CORONA Remedies Ltd. Share Price

CAPITAL GROUP BUYS NEARLY 2% STAKE IN LOTUS DEVELOPERS

LOTUSDEV US-based Capital Group has acquired a nearly 2% stake in Mumbai-based Sri Lotus Developers and Realty, while ChrysCapital-backed Sepia Investments has offloaded more than 4% of its holding in Ahmedabad-based pharmaceutical company Corona Remedies through open-market transactions. Shares of Lotus Developers reacted positively to the deal, briefly hitting the 5% upper circuit at Rs 207.88 on the NSE amid heavy trading volumes. Meanwhile, Corona Remedies recovered sharply from a gap-down opening and ended the session 0.16% higher at Rs 2,200.80. Smallcap World Fund Inc, a fund managed by California-based Capital Group, purchased 95.05 lakh shares of Lotus Developers, representing a 1.94% stake, for Rs 190.01 crore. The shares were acquired at Rs 199.89 apiece. On the selling side, promoter Anand Kamalnayan Pandit offloaded 97.7 lakh shares, equivalent to a 2% stake, for Rs 195.3 crore at Rs 199.90 per share. In Corona Remedies, Sepia Investments, an affiliate of private equity firm ChrysCapital, sold 24.85 lakh shares, representing a 4.06% stake, for Rs 509.6 crore at Rs 2,050.32 per share. The transaction was part of Sepia Investments’ 12.68% holding in the company as of June 2026. Among the buyers, SBI Mutual Fund acquired 15.4 lakh shares, or a 2.51% stake, in Corona Remedies for Rs 315.7 crore. Amundi Funds Asia Equity Concentrated also purchased 3.12 lakh shares.

Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM

CORONA Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). It focuses heavily on chronic care and therapeutic segments, capturing strong market positions:Women's Healthcare: Ranked #5 in India, reaching roughly 85% of gynecologists and IVF specialists ***** Management: Ranked #5 in India, offering formulations for acute and chronic pain ***** Ranked #20, addressing metabolic and cardiovascular ***** Ranked #9, focusing on specialist-driven urological medications.📊 Stock & Financial HighlightsCorona Remedies is a publicly traded entity on the Indian stock ***** Capitalization: Approximately ₹13,063 ***** Price: Trading at around ₹2,***** Metrics: It has delivered a strong profit growth of 23.3% CAGR over the past 5 years with a 3-year Return on Equity (ROE) of 26.5%.Dividend Yield: The company maintains a healthy dividend payout ratio of 29.4%.💡 Recent DevelopmentsThe company recently commercialised its state-of-the-art, EU-approved Women's Hormone Manufacturing Facility in Bhayla, Ahmedabad. This 1.0 lakh sq. ft. facility expands their capacity to 194 million tablets/capsules annually, driving high-margin growth in the specialized hormone therapy market.

Stock To Watch

Positives ADANIENT -To raise Rs 1000cr via NCDs (Strong technical positioning of all group stocks) ULTRACEMCO , ACC - AMBUJACEM -Cement prices improve in December IOCL, BPCL, HPCL-Brent crude falls after US invasion of Venezuala Amber Enterprises-Group received 4700 crores ECMS clearance DIXON -Gets approval to manufacture new components KPI Green Energy-Receives LOI from GUVNL RAMCO CEMENTS-Gets Andhra Pradesh Govt nod for mining lease Corona Remedies-Q2 PAT up 22% YoY Tanfac Industries-To raise Rs 500cr via QIP Nibe-Received Rs 293cr order from MoD Negatives BIRLA CORP-Rajasthan govt rejects bid for mining lease

Stocks to Watch – Market Update

Positives HDFCBANK : Received RBI approval to acquire up to 9.5% stake in INDUSINDBK , providing strategic optionality. BL Kashyap: Secured a ₹616 crore order, strengthening its order book visibility. Zydus Life: USFDA accepted a drug application for review, a positive regulatory milestone. Atlantaa: Signed a ₹500 crore pact, improving revenue prospects. GMR Airports: Passenger traffic rose 7.4% YoY in November, indicating steady recovery in air travel demand. Arvind SmartSpaces: Acquired a new real estate project, supporting growth pipeline. Ion Exchange: Bagged ₹205 crore worth of orders, enhancing execution visibility. Senores Pharma: Plans to acquire a stake in Apnar Pharma, expanding its pharmaceutical portfolio. Corona Remedies: Invesco Mutual Fund purchased 16.68 lakh shares, signaling institutional confidence. Arvind Fashions: Motilal Oswal initiated coverage with a Buy rating, target price ₹725. Negatives KNR Construction: Received a tax order of ₹72 crore, which may impact near-term sentiment. Cello World: Investec initiated coverage with a Sell rating, target price ₹530. Overall, order wins, regulatory approvals, and institutional buying dominate the positive cues, while selective tax and brokerage downgrades remain key overhangs.

🧪 Corona Remedies – IPO Listing Overview

CORONA Corona Remedies has made its market debut, drawing attention due to its strong presence in the chronic and acute pharmaceutical segments in India. The company is known for its branded formulations and consistent growth in domestic markets. 🔹 Business Strengths Strong portfolio in chronic therapies such as cardiology, diabetes, and pain management High brand recall among doctors with a large field force Healthy revenue growth and margins compared to peers Low dependence on exports, reducing regulatory and currency risks Backing of experienced promoters with long operating history 🔻 Key Weaknesses / Risks Valuations at listing appear rich, leaving limited margin of safety High dependence on domestic market limits geographic diversification Competitive pressure from large pharma players and generics Growth is largely driven by marketing strength rather than new molecule innovation Any regulatory tightening on pricing could impact margins 📊 Analyst View Most analysts have maintained a Neutral to Subscribe-for-Long-Term stance. Short-term listing gains are considered limited due to valuation comfort Long-term investors may benefit if execution and margin discipline continue Analysts prefer accumulation on corrections rather than aggressive buying at listing levels 🧠 Overall Take Corona Remedies is a fundamentally sound pharma company with strong domestic branding and steady earnings visibility. However, rich valuations cap immediate upside. Investors should track post-listing price behavior and quarterly performance before committing fresh capital.

Corona Remedies IPO

The Corona Remedies IPO looks like a play for quick listing gains rather than a solid long-term investment opportunity. Primarily focused on women's health and chronic medicines domestically, the company's existing manufacturing is already nearing full capacity. Importantly, this IPO doesn't meaningfully fund new production facilities. With most of the ₹500 crore issue being an Offer for Sale, proceeds largely go to selling shareholders, leaving little for the company's growth-focused capital expenditure – a clear negative for future expansion. While revenue and profit have grown, it's primarily driven by margin improvements and price hikes, not significant volume expansion from new internal capacity. This suggests brand strength over production capability. At roughly 40x PE and 11x PB, the valuation appears rich, especially on a price-to-book basis compared to many domestic peers, even if its India-centric focus offers some appeal. My Opinion: Ultimately, Corona Remedies boasts a strong chronic portfolio and brand, but the lack of capacity expansion and high valuations are concerns. Expect potential 20-30% listing gains, making it a viable short-term trade. For long-term investors seeking compounding growth, however, better opportunities exist.